In conclusion, the patient's quality of life was significantly improved, depression and anxiety were reduced, the patient's CD3+, CD4+, and CD4+/CD8+ indicators after treatment were higher than before treatment, and the patient's WBC, Hb, and PLT counts after treatment were lower than before treatment. This evidence concerns the gene GSTM1 and depressive symptom measurement.